NEW YORK, July 23, 2013 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
Future Prospects of Global Personalized Medicine Market 2012-2016 http://www.reportlinker.com/p01556751/Future-Prospects-of-Global-Personalized-Medicine-Market-2012-2016.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Therapy
TechNavio's analysts forecast the Global Personalized Medicine market 2012-2016 to grow at a CAGR of 12.07 percent over the period 2012-2016. One of the key factors contributing to this market growth is the significant growth of the Targeted Biologics segment. The Global Personalized Medicine market has also been witnessing an increase in the number of mergers ad acquisitions. However, the low awareness of personalized medicine in developing countries could pose a challenge to the growth of this market. TechNavio's report, the Future Prospects of Global Personalized Medicine Market 2012-2016, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market in the Americas, and the EMEA and APAC regions; it also covers the Global Personalized Medicine market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.The key vendors dominating this space include Abbott Laboratories, AstraZeneca plc, F. Hoffmann-La Roche Ltd., Novartis AG, Pfizer Inc., and Sanofi S.A.The other vendors mentioned in the report are Affymetrix Inc., Agendia B.V., Agilent Technologies Inc., Amgen Inc., Astellas Pharma Inc., Baxter International Inc., Bayer AG, BG Medicine Inc., Biocartis S.A, Biogen Idec Inc., Boehringer Ingelheim GmbH, Bristol-Myers Squibb Co., Celgene Corp., Daiichi Sankyo Co. Ltd., Danaher Corp., Eli Lilly and Co., Evotec AG, GE Healthcare Ltd., Genelex Corp., GlaxoSmithKline plc, Hologic Inc., Johnson & Johnson, Laboratory Corporation of America Holdings, Life Technologies Corp., Merck KGaA, Mitsubishi Tanabe Pharma Corp., Myriad Genetics Inc., Novartis AG, PerkinElmer Inc., Pfizer Inc., Quest Diagnostics Inc., Sanofi S.A., Siemens Healthcare, Sigma-Aldrich Corp., Takeda Pharmaceutical Co. Ltd., Teva Pharmaceutical Industries Ltd., Thermo Fisher Scientific Inc., and Transgenomic Inc.